France to Reimburse Anti-Obesity Drugs, Minister Says
France will cover 65% of the cost, with most patients receiving full reimbursement because they have related conditions, the health minister said.
- French Health Minister Stéphanie Rist announced on Thursday that France will begin reimbursing weight-loss drugs Wegovy and Mounjaro starting 15 June, becoming the first European Union nation to provide permanent, standard coverage.
- The decision targets severe obesity, limiting coverage to patients with a BMI of 35 or more with a weight-related comorbidity, or a BMI of at least 40, addressing a population where around 18% of the French population are obese.
- Officially, the reimbursement rate is 65%, but Rist noted that for the vast majority of patients with comorbidities like diabetes or hypertension, coverage will be 100%, costing around €100 million annually.
- Meanwhile, US pharmacy benefit manager CVS Health is restoring coverage for Eli Lilly's Zepbound after excluding it last year, as sales of the drug grew 122% in the fourth quarter.
- Rist stated the policy targets "around one million people" in France, positioning the country alongside the UK as an outlier in providing permanent reimbursement for weight-loss treatments within the European Union.
18 Articles
18 Articles
From 15 June, these two medicines, which cost around 300 euros per month, will be reimbursed in France to 65% by sickness insurance. According to the Minister of Health, Stéphanie Rist, one million people should be covered.
Zero Hedge
Nemos News NetworkFrance To Reimburse Patients For Anti-Obesity Drugs
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Reimbursement will come into effect by mid-June.
France will begin to decontest the medicines for weakness as of June 15th, the French Minister of Health, Stéphanie Rist, announced Thursday. Through this decision, the country becomes the first European state to cover the costs of these types of treatments.
The reimbursement of new anti-obesity treatments was formalized on Thursday only for some patients with the most severe obesity. These drugs, among the most sold in the pharmaceutical industry, have profoundly transformed the care of millions of patients in the world. How do they work? - Anti-obesity medicines: Wegovy, Mounjaro, Ozempic... how do they work? (Health and well-being).
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
